2 terminated, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow BMS 754807: new trials by email Literature Review of BMS 754807 trials Research Report on BMS 754807
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors BMS-754807, letrozole - Breast Cancer | Phase 2 | Terminated | Bristol-Myers Squibb | 77 | 2010-12-31 | 2020-08-11 |
| Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors BMS-754807, cetuximab (Erbitux®) - Colorectal Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 54 | 2009-10-01 | 2013-06-18 |
| Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer BMS-754807, trastuzumab (Herceptin®) - Breast Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 40 | 2009-07-01 | 2012-07-13 |
Breast Neoplasms (2) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1)
Canada (2) · United States (2) · Australia (1) · Belgium (1) · Hungary (1) · United Kingdom (1)